Correspondence 0001193125-24-245562 from OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715) (OKUR)
OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715)
Date: Oct. 28, 2024 · CIK: 0001637715 · Accession: 0001193125-24-245562
AI Filing Summary & Sentiment
File numbers found in text: 333-282792
Letter
Re: OnKure Therapeutics, Inc.
October 28, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Doris Stacey Gama
Registration Statement on Form S-1
File No. 333-282792
Acceleration Request
Requested Date: October 30, 2024
Requested Time: 4:30 p.m. Eastern Time, or as soon thereafter as practicable
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, OnKure Therapeutics, Inc. (the “Company”) hereby requests that its Registration Statement on Form S-1 (File No. 333-282792) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041.
Sincerely,
ONKURE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP October 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: OnKure Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-282792 Acceleration Request Requested Date: October 30, 2024 Requested Time: 4:30 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, OnKure Therapeutics, Inc. (the “Company”) hereby requests that its Registration Statement on Form S-1 (File No. 333-282792) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041. Sincerely, ONKURE THERAPEUTICS, INC. By: /s/ Nicholas A. Saccomano Nicholas A. Saccomano Chief Executive Officer cc: Jennifer Knapp, Wilson Sonsini Goodrich & Rosati